MedTrace Logo

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

NCT05612581 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-02-09

Study results available
· View outcomes & findings →

Summary

This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

TDF

TDF given orally

DRUG

PEG-IFNα

PEG-IFNα given by subcutaneous injection

Sponsors & Collaborators

  • Vir Biotechnology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-10-15
Completion
2025-08-19
FDA Drug
Yes

Countries

  • France
  • Hong Kong
  • Moldova
  • Romania
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612581 on ClinicalTrials.gov